Review Article
Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment
Daniel Orivea,b,c, Mirari Echeparea,b,c,d, Franco Bernasconi-Bisioe,f, Miguel Fernández Sanmamedc,g,h, Antonio Pineda-Lucenad,e,f, Carlos de la Calle-Arroyoi, Frank Detterbeckj, Rayjean J. Hungk,l, Mattias Johanssonm, Hilary A. Robbinsm, Luis M. Seijon,o, Luis M. Montuengaa,b,c,d,
, Karmele Valenciaa,c,d,f,
Corresponding author
Corresponding author
a Solid Tumors Program, CIMA-University of Navarra, Pamplona, Spain
b Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain
c Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
d Navarra Health Research Institute (IDISNA), Pamplona, Spain
e Molecular Therapeutics Program, CIMA-University of Navarra, Pamplona, Spain
f Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain
g Program of Immunology and Immunotherapy, CIMA-University of Navarra, Pamplona, Spain
h Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
i Instituto de Ciencia de los Datos e Inteligencia Artificial (DATAI), Universidad de Navarra, Pamplona, Spain
j Division of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT, USA
k Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada
l Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
m International Agency for Research on Cancer, Lyon, France
n CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain
o Pulmonary Department, Clínica Universidad de Navarra, Madrid, Spain
Ver más
